BrainsWay Ltd

BWAY

Company Profile

  • Business description

    BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

  • Contact

    16 Hartum Street
    14th Floor, RAD Tower
    Har HaHotzvim
    Jerusalem9777516
    ISR

    T: +972 25824030

    https://www.brainsway.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    129

Stocks News & Analysis

stocks

Avoid this overvalued ASX healthcare share

Expensive healthcare share limited by its core addressable market.
stocks

AI driving growth for ASX tech share

ASX tech share raises funds to facilitate customer AI spend.
stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,824.8067.500.77%
CAC 408,203.434.140.05%
DAX 4024,433.06183.16-0.74%
Dow JONES (US)50,872.1186.100.17%
FTSE 10010,227.33145.87-1.41%
HKSE24,565.9091.16-0.37%
NASDAQ25,678.82250.84-0.97%
Nikkei 22565,416.631,392.032.17%
NZX 50 Index13,163.1940.89-0.31%
S&P 5007,386.6519.08-0.26%
S&P/ASX 2008,604.2070.700.83%
SSE Composite Index4,010.0350.691.28%

Market Movers